Htg Molecular Diagnostics Stock Revenue
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
HTG Molecular Diagnostics fundamentals help investors to digest information that contributes to HTG Molecular's financial success or failures. It also enables traders to predict the movement of HTG Stock. The fundamental analysis module provides a way to measure HTG Molecular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HTG Molecular stock.
HTG |
HTG Molecular Diagnostics Company Revenue Analysis
HTG Molecular's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current HTG Molecular Revenue | 6.37 M |
Most of HTG Molecular's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HTG Molecular Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, HTG Molecular Diagnostics reported 6.37 M of revenue. This is 99.92% lower than that of the Health Care Technology sector and 99.68% lower than that of the Health Care industry. The revenue for all United States stocks is 99.93% higher than that of the company.
HTG Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HTG Molecular's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HTG Molecular could also be used in its relative valuation, which is a method of valuing HTG Molecular by comparing valuation metrics of similar companies.HTG Molecular is currently under evaluation in revenue category among its peers.
HTG Fundamentals
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 6.37 M | |||
| Gross Profit | (2.01 M) | |||
| EBITDA | (20.14 M) | |||
| Net Income | (21.59 M) | |||
| Cash And Equivalents | 14.1 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 4.83 M | |||
| Debt To Equity | 2.52 % | |||
| Current Ratio | 1.90 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (18.41 M) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | (17.10) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 53 | |||
| Beta | 0.99 | |||
| Market Capitalization | 1.06 M | |||
| Total Asset | 17.78 M | |||
| Retained Earnings | (229.93 M) | |||
| Working Capital | 7.38 M | |||
| Current Asset | 34.86 M | |||
| Current Liabilities | 6.32 M | |||
| Z Score | -20.86 | |||
| Net Asset | 17.78 M |
About HTG Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HTG Molecular Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HTG Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HTG Molecular Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |